Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.41 |
| ▸ | ITGAV | P06756 | 2/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.41 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.40 |
| ▸ | MC4R | P32245 | 11/20 | 0.39 |
| ▸ | MC5R | P33032 | 11/20 | 0.39 |
| ▸ | MC3R | P41968 | 11/20 | 0.39 |
| ▸ | MC1R | Q01726 | 11/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13659873 | 0.93 | IL23R (0.45) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL13659868 | 0.85 | IL23R (0.48) | ITGB3ITGAVIL23RMC4RMC5R | |
| SCHEMBL14962599 | 0.83 | ITGB3 (0.46) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL13649562 | 0.82 | MC4R (0.49) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL26200764 | 0.81 | ITGB3 (0.49) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL10046561 | 0.81 | ITGB3 (0.49) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL26200836 | 0.81 | ITGB3 (0.49) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL10046406 | 0.81 | ITGB3 (0.49) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL22004632 | 0.78 | ITGB3 (0.47) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL13870331 | 0.78 | MC4R (0.48) | ITGB3ITGB1ITGAVITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361443-B2 | Peptide-based compounds | GE HEALTHCARE AS (NO) | 2013-01-29 | — | — | US | disclosed |
| US-20090263320-A1 | Peptide-Based Compounds | GE HEALTHCARE AS (NO) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263320-A1 | Peptide-Based Compounds | ITGB3, ITGAV, SELPLG | ITGB3 1/4885ITGB1 4/4885ITGAV 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.